GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Margin of Safety % (DCF Dividends Based)

Innovent Biologics (HKSE:01801) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Innovent Biologics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.


Competitive Comparison of Innovent Biologics's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Innovent Biologics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Margin of Safety % (DCF Dividends Based) falls into.



Innovent Biologics Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (HKSE:01801) Business Description

Industry
Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Yu De-chao Michael 2101 Beneficial owner
Temasek Holdings (private) Limited
Brown Brothers Harriman & Co. 2502 Approved lending agent
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Eight Roads Investments 2101 Beneficial owner
Fullerton Management Pte Ltd 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited 2201 Interest of corporation controlled by you
Tls Beta Pte. Ltd. 2101 Beneficial owner

Innovent Biologics (HKSE:01801) Headlines

No Headlines